Plain-English translation of NCT02818517 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Heart Failure research guide →Cancer treatments like chemotherapy and radiation can sometimes damage the heart, even years after treatment ends. This study is building a registry to carefully monitor cancer patients' heart health and identify who is at highest risk for heart damage. Researchers will also evaluate whether heart medications called ACE inhibitors and beta blockers can help prevent these problems.
More cancer patients are surviving longer thanks to better treatments, but heart damage from those same treatments is becoming a major concern—sometimes causing more deaths than cancer recurrence itself. Right now, doctors don't have clear guidelines for how to monitor and prevent this heart damage, so this study aims to fill that gap.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be part of a registry that tracks your health over time. You'll have clinical check-ups, blood tests to measure heart markers, and heart imaging (echocardiogram) to look for any signs of damage. Some participants will be included based on past clinic visits (if you were seen between 2014–2016), while others will be followed going forward from June 2016. Your doctors will use this information to catch heart problems early and decide if heart medications might help protect you.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
Israel
Enrollment target
~1,000 participants
Started
August 2016
Primary completion
November 2030
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2022.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Michal Laufer Perl, MD
Tel Aviv MC
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.